Showing results (171-180 of 453) with videos related to

Sort By:
Pageof 46
Cancer Research|November 29, 2018
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAnessJianfeng Shen, Wei Zhao, Zhenlin Ju, et al.
Investigational New Drugs|March 22, 2014
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJordi Rodon, Irene Braña, Lillian L Siu, et al.
Frontiers in Veterinary Science|October 1, 2025
On-site detection of MERS-CoV infections in a camel slaughterhouse in Kenya using a commercial rapid antigen testBrian Maina Ogoti, Victor Riitho, Jordi Rodon, et al.
Investigational New Drugs|May 18, 2026
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancerJordi Rodon, Bert O'Neil, Christopher Lim, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 5, 2026
Epidemiology and genomic features of MERS coronavirus in Africa: a systematic and meta-analysis reviewBrian Ogoti, Victor Riitho, Johanna Wildemann, et al.
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Veterinary Pathology|December 27, 2021
Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic miceEnric Vidal, Carlos López-Figueroa, Jordi Rodon, et al.
Cancers|August 23, 2020
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and ParagangliomasCamilo Jimenez, Vivek Subbiah, Bettzy Stephen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2024
Oncology Combination Drug Development Strategies for Project OptimusTimothy A Yap, Julie Bullock, Susan Chong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3AKyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, et al.
Pageof 46